Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Says Bayer Rep Contacted It Last July over Xarelto Survey, Issue Should Be First Handled by Regulators
April 24, 2017
- PhRMA Submits Paper to Lawmaker Group, Demands Price Maintenance for On-Patent Drugs
April 21, 2017
- Innovation Premium Top Priority for 3 Trade Groups; EFPIA Ideally Wants Its Expansion
April 20, 2017
- Masaru Nakamura Resigns as Chairman of NPhA in Wake of False Claim Scandal Involving Qol
April 18, 2017
- PhRMA Chair Repeats Call for Keeping Price Maintenance Premium to Secure Market Predictability
April 13, 2017
- JGA Fires Back at Criticism on “Excessive” and “Expensive” Generics, Says No. of Makers Not So Many
April 11, 2017
- Asian Industry Groups Promote Collaboration to Discover Drugs from Natural Resources by Leveraging Asia’s Diverse Ecosystems
April 10, 2017
- JPMA to Support Japanese Drug Makers’ Overseas Expansion through Public-Private Cooperation
April 10, 2017
- Tap Tax Cuts and AMED Subsidies, not Price Premium, to Fuel Innovation: JMA Chief
April 7, 2017
- 26 Japan CRO Association Members Enjoy 12.7% Sales Jump in 2016
April 6, 2017
- Kampo Study Group Submits Proposal to LDP Lawmakers, Cites “Concerns About Stable Supply at Current NHI Prices”
April 6, 2017
- 3 Groups Lay Out Guidelines on Inter-Pharmacy Drug Transactions after Harvoni Flub
April 4, 2017
- GHIT Fund to Invest a Total of US$23 Million in 11 Projects
April 3, 2017
- Generic Use Rate at 66.4% in October-December: JGA
March 31, 2017
- Wholesalers to Address Product Return Issue after Fake Harvoni Case: JPWA Chair
March 28, 2017
- Vaccine Association to Standardize Presentation of Expiration Dates above Inspection Dates on Outer Packaging
March 27, 2017
- FPMAJ to Keep Ex-Bureaucrat Kimura as Director General to Secure Lobbying Continuity
March 24, 2017
- JPMA Reprimands Celgene over Side Effect Reporting Violation
March 24, 2017
- Use “Specified Clinical Research” Data for Drug Approval: Regulatory Science Society
March 23, 2017
- Study Group Presents Proposal for Future Vision for Kampo Medicines
March 21, 2017
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…